Sepsis, Coagulation, and Antithrombin: Old Lessons and New Insights

ABSTRACT

Current insights in the pathogenesis of multiple organ dysfunction in patients with sepsis point to a pivotal role of inflammation and coagulation. One of the most important mechanisms contributing to the activation of coagulation in sepsis is the downregulation of physiologic anticoagulant systems, such as the antithrombin pathway. More than 20 years ago, Eberhard Mammen already hypothesized that coagulation activation and antithrombin were important factors in patients with sepsis. Abundant experimental and clinical studies have supported that notion in recent years. The better understanding of the pathogenesis of coagulation activation and the role of natural anticoagulants in sepsis has led to the development of anticoagulant factor concentrates, such as antithrombin concentrate. Clinical studies indicate that these interventions may have a role in the (supportive) treatment of patients with sepsis, mostly based on surrogate outcomes, but ongoing studies will have to confirm a beneficial effect in reducing mortality.

Sepsis - coagulation - thrombosis - antithrombin

REFERENCES

• 1 Strieter R M, Lynch III J P, Basha M A, Standiford T J, Kasahara K, Kunkel S L. Host responses in mediating sepsis and adult respiratory distress syndrome.  Semin Respir Infect. 1990;  5 233-247
• 2 Mammen E F. The haematological manifestations of sepsis.  J Antimicrob Chemother. 1998;  41(Suppl A) 17-24
• 3 Mammen E F. Disseminated intravascular coagulation (DIC).  Clin Lab Sci. 2000;  13 239-245
• 4 Wheeler A P, Bernard G R. Treating patients with severe sepsis.  N Engl J Med. 1999;  340 207-214
• 5 Levi M, van der Poll T, Buller H R. Bidirectional relation between inflammation and coagulation.  Circulation. 2004;  109 2698-2704
• 6 Levi M. Disseminated intravascular coagulation.  Crit Care Med. 2007;  35 2191-2195
• 7 Levi M, Keller T T, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system.  Cardiovasc Res. 2003;  60 26-39
• 8 Robboy S J, Major M C, Colman R W, Minna J D. Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases.  Hum Pathol. 1972;  3 327-343
• 9 Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation.  Arch Pathol Lab Med. 1983;  107 543-547
• 10 Creasey A A, Chang A C, Feigen L, Wun T C, Taylor F BJ, Hinshaw L B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.  J Clin Invest. 1993;  91 2850-2856
• 11 Kessler C M, Tang Z, Jacobs H M, Szymanski L M. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity.  Blood. 1997;  89 4393-4401
• 12 Taylor F BJ, Chang A, Ruf W et al.. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody.  Circ Shock. 1991;  33 127-134
• 13 Taylor F BJ, Chang A, Esmon C T, D'Angelo A, Vigano-D'Angelo S, Blick K E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.  J Clin Invest. 1987;  79 918-925
• 14 Welty-Wolf K E, Carraway M S, Miller D L et al.. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons.  Am J Respir Crit Care Med. 2001;  164 1988-1996
• 15 Miller D L, Welty-Wolf K, Carraway M S et al.. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide.  Am J Respir Cell Mol Biol. 2002;  26 650-658
• 16 Levi M, ten Cate H. Disseminated intravascular coagulation.  N Engl J Med. 1999;  341 586-592
• 17 Fourrier F, Chopin C, Goudemand J et al.. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.  Chest. 1992;  101 816-823
• 18 Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients.  Semin Thromb Hemost. 2008;  34 459-468
• 19 Laterre P F, Wittebole X, Collienne C. Pharmacological inhibition of tissue factor.  Semin Thromb Hemost. 2006;  32 71-76
• 20 Taylor F BJ, Dahlback B, Chang A C et al.. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli.  Blood. 1995;  86 2642-2652
• 21 Esmon C T. Inflammation and the activated protein C anticoagulant pathway.  Semin Thromb Hemost. 2006;  32(Suppl 1) 49-60
• 22 Levi M, Dorffler-Melly J, Reitsma P H et al.. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice.  Blood. 2003;  101 4823-4827
• 23 Mammen E F. Antithrombin III and sepsis.  Intensive Care Med. 1998;  24 649-650
• 24 Balk R, Emerson T, Fourrier F et al.. Therapeutic use of antithrombin concentrate in sepsis.  Semin Thromb Hemost. 1998;  24 183-194
• 25 Mammen E F. Antithrombin: its physiological importance and role in DIC.  Semin Thromb Hemost. 1998;  24 19-25
• 26 Dickneite G. Antithrombin III in animal models of sepsis and organ failure.  Semin Thromb Hemost. 1998;  24 61-69
• 27 Minnema M C, Chang A C, Jansen P M et al.. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli.  Blood. 2000;  95 1117-1123
• 28 Taylor F BJ, Emerson T EJ, Jordan R, Chang A K, Blick K E. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons.  Circ Shock. 1988;  26 227-235
• 29 Leitner J M, Firbas C, Mayr F B, Reiter R A, Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia.  Clin Pharmacol Ther. 2006;  79 23-34
• 30 Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells.  Thromb Res. 1990;  59 895-904
• 31 Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin.  Blood. 1999;  93 157-164
• 32 Mizutani A, Okajima K, Uchiba M et al.. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production.  Blood. 2003;  101 3029-3036
• 33 Ostrovsky L, Woodman R C, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion.  Circulation. 1997;  96 2302-2310
• 34 Levi M, van der Poll T. Two-way interactions between inflammation and coagulation.  Trends Cardiovasc Med. 2005;  15 254-259
• 35 Nieuwdorp M, Meuwese M C, Mooij H L et al.. Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation.  Atherosclerosis. 2008;  202 296-303
• 36 Vink H, Constantinescu A A, Spaan J A. Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion.  Circulation. 2000;  101 1500-1502
• 37 van den Berg B M, Vink H, Spaan J A. The endothelial glycocalyx protects against myocardial edema.  Circ Res. 2003;  92 592-594
• 38 Esmon C T. Role of coagulation inhibitors in inflammation.  Thromb Haemost. 2001;  86 51-56
• 39 Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.  Crit Care Med. 2001;  29 S90-S94
• 40 Mesters R M, Mannucci P M, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.  Blood. 1996;  88 881-886
• 41 Bernard G R, Vincent J L, Laterre P F et al.. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
• 42 Levi M, ten Cate H, van der Poll T. Disseminated intravascular coagulation: state of the art.  Thromb Haemost. 1999;  82 695-705
• 43 Warren B L, Eid A, Singer P et al.. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286 1869-1878
• 44 Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study.  Thromb Res. 1985;  39 81-89
• 45 Bishop J R, Schuksz M, Esko J D. Heparan sulphate proteoglycans fine-tune mammalian physiology.  Nature. 2007;  446 1030-1037
• 46 Baranska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A. Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids.  J Antimicrob Chemother. 2006;  57 260-265
• 47 Parish C R. The role of heparan sulphate in inflammation.  Nat Rev Immunol. 2006;  6 633-643
• 48 Gotte M. Syndecans in inflammation.  FASEB J. 2003;  17 575-591
• 49 Lindahl U. Heparan sulfate-protein interactions—a concept for drug design?.  Thromb Haemost. 2007;  98 109-115
• 50 Xie X, Rivier A S, Zakrzewicz A et al.. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate.  J Biol Chem. 2000;  275 34818-34825
• 51 Levi M. Antithrombin in sepsis revisited.  Crit Care. 2005;  9 624-625
• 52 Bernard G R, Ely E W, Wright T J et al.. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.  Crit Care Med. 2001;  29 2051-2059
• 53 Taylor F BJ, Toh C H, Hoots W K, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.  Thromb Haemost. 2001;  86 1327-1330
• 54 Dhainaut J F, Yan S B, Joyce D E et al.. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.  J Thromb Haemost. 2004;  2 1924-1933